BDNF, TNFα, HSP90, CFH, and IL-10 Serum Levels in Patients with Early or Late Onset Alzheimer's Disease or Mild Cognitive Impairment
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Identifying early-detection biomarkers have become an increasingly important approach in the treatment and prevention of Alzheimer's disease (AD). In this study, we investigated the potential of brain-derived neurotrophic factor (BDNF), complement factor H (CFH), tumor necrosis factor-α (TNFα), interleukin 10 (IL-10), and heat shock protein 90 (Hsp90) as serum biomarkers for AD in a cohort of the Turkish population because they have been suggested to be associated with AD. Serum BDNF, CFH, TNFα, IL-10, and Hsp90 levels in three groups of patients, early-onset AD (EOAD; age of onset 65; n = 54), and mild cognitive impairment (MCI) (n = 30), were compared with age-matched healthy controls (age 65; n = 32) using ELISA. The serum BDNF levels significantly decreased and TNFα levels significantly increased in the EOAD and LOAD groups compared to the age-matched healthy controls. There was a correlation between serum TNFα and IL-10 levels in the LOAD and healthy control groups. Serum CFH levels in the LOAD and MCI patients were significantly decreased compared with controls. Serum Hsp90 levels in the EOAD, LOAD, and MCI patients were significantly decreased compared with controls. The protein misfolding, the inflammatory response, and decreased neurotrophic factor synthesis are all suggested to be related to AD type brain pathology, and our results indicate these alterations might be traced from serum samples. For accurate early diagnosis of AD, it is important to determine a profil…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“as well as in AD patients’ CSF and serum [215,216,217,218,219,220,221,222]”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [221]
In the citing paper
“In humans, two studies have shown an increase in pro-inflammatory cytokines and a decrease in BDNF levels in the serum of early- and late-onset AD, although there was no correlation with pro-inflammatory and neurotrophin results in both studies [141, 156].”
From Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation (2019) · cites this paper as [141]
In the citing paper
“BDNF levels are also reduced in plasma of patients with mild cognitive impairment (MCI) [140] and AD [141].”
From Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation (2019) · cites this paper as [141]
Citations
Cites
Potential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867 · cited 1×
“…plasticity, neuronal neuronal survival, and differentiation, where it participates BDNF mRNA and protein levels in the hippocampus and neocortex of AD patients suggest that BDNF of BDNF have been reported in the hippocampus [9 and BDNF can mediate rapid dephosphorylation of tau protein [4].”
Brain-derived neurotrophic factor is reduced in Alzheimer's disease
Connor, B., Young, D., Yan, Q., Faull, R. L. M., Synek, B., & Dragunow, M. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00125-3 · Cited by 581
New insights into brain BDNF function in normal aging and Alzheimer disease
Tapia-Arancibia, L., Aliaga, E., Silhol, M., & Arancibia, S. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.07.007 · Cited by 571
Proteome-based plasma biomarkers for Alzheimer's disease
Hye, A., Lynham, S., Thambisetty, M., Causevic, M., Campbell, J., Byers, H. L., Hooper, C., Rijsdijk, F., Tabrizi, S. J., Banner, S., et al. (2006) · Brain · doi:10.1093/brain/awl279 · Cited by 464
Heat Shock Proteins 70 and 90 Inhibit Early Stages of Amyloid β-(1–42) Aggregation in Vitro
Evans, C. G., Wisén, S., & Gestwicki, J. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606192200 · Cited by 382 · cited 1×
“Studies suggest that chaperones may have role in AD [30, 31].”
Neurotrophic factors in Alzheimer’s disease: role of axonal transport
Schindowski, K., Belarbi, K., & Buée, L. (2008) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2007.00378.x · Cited by 335
Holsinger, R. M. D., Schnarr, J., Henry, P., Castelo, V. T., & Fahnestock, M. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00023-1 · Cited by 328
Laske, C., Stransky, E., Leyhe, T., Eschweiler, G. W., Maetzler, W., Wittorf, A., Soekadar, S., Richartz, E., Koehler, N., Bartels, M., et al. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.01.014 · Cited by 272
Magrané, J., Smith, R. C., Walsh, K., & Querfurth, H. W. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4330-03.2004 · Cited by 242
Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients
Laske, C., Stellos, K., Hoffmann, N., Stransky, E., Straten, G., Eschweiler, G. W., & Leyhe, T. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001008 · Cited by 180
Cited by
Items 101–195 of 195
Are Heat Shock Proteins an Important Link between Type 2 Diabetes and Alzheimer Disease?
Rowles, J., Keane, K. N., Heck, T. G., Cruzat, V. F., Verdile, G., & Newsholme, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218204 · Cited by 35
TNF-alpha G308A Polymorphism and the Susceptibility to Alzheimer's Disease: An Updated Meta-analysis
Wang, T. (2015) · Archives of Medical Research · doi:10.1016/j.arcmed.2014.12.006 · Cited by 29
Wei, W., Yao, J., Zhang, T., Wen, J., Zhang, Z., Luo, Y.-M., Cao, Y., & Li, H. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1059496 · Cited by 31
“Furthermore, we determined the relative expression changes of the main targets in AD mice by RT-qPCR, and found that Akt1, Hsp90aa1, Hras, and Igf1 mRNA levels were significantly altered after BBR treatment.”
BackgroundInfluentialPrieto-Almeida, F., Panveloski-Costa, A. C., Crunfli, F., Teixeira, S. D. S., Nunes, M. T., & Torrão, A. D. S. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.11.013 · Cited by 32
Biomarcadores sanguíneos en la enfermedad de Alzheimer
Altuna, M., & Mendióroz, M. (2018) · Neurología · doi:10.1016/j.nrl.2018.03.006 · Cited by 31
Ismail, N. A., Abdullah, M. F. I. L. B., Hami, R. B., & Yusof, H. A. (2020) · Growth Factors · doi:10.1080/08977194.2020.1864347 · Cited by 27
“In some studies, decreased level of BDNF have been documented in AD patients (Laske et al. 2007; Leyhe et al. 2008; Jung et al. 2009; Erickson et al. 2010; Forlenza et al. 2010; Gezen-Ak et al. 2013; Borba et al. 2016; Alvarez et al. 2014; Ventriglia et al. 2013; Laske et al. 2011).”
BackgroundSelective PPAR-Delta/PPAR-Gamma Activation Improves Cognition in a Model of Alzheimer’s Disease
Steinke, I., Govindarajulu, M., Pinky, P. D., Bloemer, J., Yoo, S., Ward, T., Schaedig, T., Young, T., Wibowo, F. S., Suppiramaniam, V. D., et al. (2023) · Cells · doi:10.3390/cells12081116 · Cited by 26
Let’s make microglia great again in neurodegenerative disorders
Guillot‐Sestier, M., & Town, T. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1792-x · Cited by 31
“…are abnormally elevated in AD patients’ sera and brains and in rodent models of the disease (Angelopoulos et al. 2008; Loewenbrueck et al. 2010; Gezen-Ak et al. 2013; Asse- lineau et al. 2015; Guillot-Sestier et al. 2015a, b), and recent GWAS/integrative genomics studies validate…”
Eyileten, C., Mirowska-Guzel, D. M., Milanowski, Ł., Zaremba, M., Rosiak, M., Cudna, A., Kapłon‐Cieślicka, A., Opolski, G., Filipiak, K. J., Małek, Ł. A., et al. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.01.014 · Cited by 25
Serna-Orozco, M. F., Mosquera, M., & García‐Perdomo, H. A. (2025) · NeuroMolecular Medicine · doi:10.1007/s12017-025-08866-w · Cited by 25
“…al., 2002; Delaby et al., 2015; Dubenko et al., 2021; Dursun et al., 2015; Fenoglio et al., 2004; Forlenza et al., 2009; Gal-imberti et al., 2006; Gezen-Ak et al., 2013; Gongora-Rivera et al., 2020; Gorska-Ciebiada et al., 2015; Gross et al., 2019; Gupta et al., 2017; Hazen et al., 2020; Hesse…”
Juniarti, N., Mz, I. A. A., Sari, C. W. M., & Haroen, H. (2021) · Journal of Aging Research · doi:10.1155/2021/6647029 · Cited by 24
A review on gut microbiota and miRNA crosstalk: implications for Alzheimer’s disease
Ayyanar, M. P., & Vijayan, M. (2024) · GeroScience · doi:10.1007/s11357-024-01432-5 · Cited by 25
“NF-kB activation by LPS triggers pro-inflammatory miRNAs (e.g., miRNA-146a, miRNA-155), which regulate CFH expression in the brain and retina, potentially exacerbating inflammatory pathology in AD and macular degeneration associated with age [260–262].”
Martins, T. S., Marçalo, R., Ferreira, M., Vaz, M., Silva, R. M., Rosa, I. M., Vogelgsang, J. S., Wiltfang, J., Silva, O. A. B. D. C. E., & Henriques, A. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083933 · Cited by 23
Blood-Based Biomarkers of Alzheimers Disease: Diagnostic Algorithms and New Technologies
Carmona, P., Molina, M., & Tolédano, A. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666151116130301 · Cited by 23
Lu, G., Liu, W., Huang, X., & Zhao, Y. (2020) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20190151 · Cited by 23
Mansour, H. M., Mohamed, A. F., Khattab, M. M., & El-Khatib, A. S. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.114069 · Cited by 21
Liu, X., Yamashita, T., Shang, J., Shi, X., Morihara, R., Huang, Y. C., Sato, K., Takemoto, M., Hishikawa, N., Ohta, Y., et al. (2019) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2019.104310 · Cited by 20
Li, L., Guo, H., Lai, B., Liang, C., Chen, H., Chen, Y., Guo, W., Yuan, Z., Huang, R., Zeng, Z., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.967463 · Cited by 19
The Protective Effect of IDO1 Inhibition in Aβ-Treated Neurons and APP/PS1 Mice
Duan, Z., Shi, L., He, Z. N. T., Kuang, C., Han, T., & Yang, Q. (2023) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175231214861 · Cited by 23
“50 We discovered in the hippocampus, the mRNA levels of IFN-γ , TNF-α , IL-1 β in the IDO1 inhibitor and Donepezil groups were lower than the control group, while the mRNA level of IL-10 was signi fi cantly increased in the IDO1 inhibitor group (Figure 5A).”
BackgroundBrain Aging: Hsp90 and Neurodegenerative Diseases
Wang, K., Shang, Y., & Dou, F. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1117-8_6 · Cited by 19
Singh, R. K. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04369-7 · Cited by 19
Zhang, K., Li, B., Gu, Z., Hou, Z., Liu, T., Zhao, J., Ruan, M., Zhang, T., Yu, Q., Yu, X., et al. (2023) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2023.104946 · Cited by 19
Plasma Complement factor H in Alzheimer's Disease
Williams, M. A., Haughton, D. J., Stevenson, M., Craig, D., Passmore, A. P., & Silvestri, G. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142742 · Cited by 18
Sarkaki, A., Farbood, Y., Badavi, M., Ghadiri, A., Dehcheshmeh, M. G., Mansouri, E., & Navabi, S. P. (2018) · Microcirculation · doi:10.1111/micc.12503 · Cited by 19
Shateri, S., Khatami, S. H., Toutounchi, A. H., Rajaei, S., Mahdavi, M., Baram, S. M., Shahidi, G. A., Habibi, A. H., Aghamollaii, V., Ghlichnia, B., et al. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2023.2292951 · Cited by 19
“…the control group (both p < 0.0001). these results are consistent with those reported by Belkhelfa et al. Gezen-ak et al. and Galimberti et al. [53,56,62]. the serum levels of il-1α, il-1β, il-4, il-6, il-8, il-10, il-12p70, tNF-α, iP-10, and McP-1 were significantly higher in patients with PD…”
InfluentialElevated glycemia and brain glucose utilization predict BDNF lowering since early life
Guzzardi, M. A., Sanguinetti, E., Bartoli, A., Kemeny, A., Panetta, D., Salvadori, P. A., Burchielli, S., & Iozzo, P. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17697338 · Cited by 17
Marino, A., Restivo, V., Baschi, R., Bavisotto, C. C., Cefalu, A. B., Accardi, G., de Macario, E. C., Macario, A. J. L., Cappello, F., & Monastero, R. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180825 · Cited by 16
Pérez-Martín, E., Pérez-Revuelta, L., Barahona-López, C., Pérez-Boyero, D., Alonso, J. R., Díaz, D., & Weruaga, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119691 · Cited by 16
“This result would support the putative role of TNFα as an early onset biomarker of neurodegeneration, as proposed by other authors [51,53].”
ResultTaipa, R. J. F., Sousa, A. L., Pires, M. M., & Sousa, N. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160121 · Cited by 16
Tsai, C., Sun, H., Kuo, Y., & Pai, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101639 · Cited by 16
Holland, J. F., Cosgrove, D., Whitton, L., Harold, D. H., Corvin, A. P., Gill, M., Mothersill, D., Morris, D. W., & Donohoe, G. J. (2019) · Genes Brain & Behavior · doi:10.1111/gbb.12602 · Cited by 16
Inflammation in the CNS: Understanding Various Aspects of the Pathogenesis of Alzheimer's Disease
Doroszkiewicz, J., Mroczko, P., & Kulczyńska‐Przybik, A. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666211202143935 · Cited by 15
Acupuncture promotes expression of Hsp84/86 and delays brain ageing in SAMP8 mice
Chang, S., Guo, X., Li, G., Zhang, X., Li, J., Jia, Y., & Nie, K. (2019) · Acupuncture in Medicine · doi:10.1136/acupmed-2017-011577 · Cited by 18
Tsai, C., Erickson, K. I., Sun, H., Kuo, Y., & Pai, M. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.113268 · Cited by 14
Warpechowski, M., Warpechowski, J. J., Kulczyńska‐Przybik, A., & Mroczko, B. (2022) · Medical Science Monitor · doi:10.12659/msm.938826 · Cited by 15
Antiglycative activity of sulforaphane: a new avenue to counteract neurodegeneration?
Hrelia, S., Angeloni, C., & Malaguti, M. (2015) · Neural Regeneration Research · doi:10.4103/1673-5374.169613 · Cited by 11
“BDNF expression levels are reduced in the brain of AD patients and the importance of BDNF in AD pathophysiology leads to the proposal of BDNF serum levels as a biomarker of AD risk (Gezen-Ak et al., 2013).”
BackgroundWang, D., Di, X., Fu, L., Li, Y., Han, X., Wu, H., Cai, L., Meng, X., Jiang, C., Kong, W., et al. (2016) · Neuroreport · doi:10.1097/wnr.0000000000000661 · Cited by 12
Heat Shock Proteins in Multiple Sclerosis
Ortan, P., Ozden, Y. A., Erkızan, Ö., & Gedizlioğlu, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-47861-6_3 · Cited by 13
Scaini, G., Morais, M. O. D. S., Furlanetto, C. B., Kist, L. W., Pereira, T. C. B., Schuck, P. F., Ferreira, G. C., Pasquali, M. A. D. B., Gelain, D. P., Moreira, J. C. F., et al. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1541-1 · Cited by 15
“Moreover, BDNF plays a pivotal role in age-related memory impairments and is associated with age-related atrophy of the hippocampus and have been shown to be altered in Alzheimer’s disease [35], mild cognitive impairment [36, 37], major depression disorder, and depressive symptoms [38–41].”
BackgroundSordu, P., Alaylıoğlu, M., Samancı, B., Bulu, E., Güleç, Z. E. K., Bılgıç, B., Hanagasi, H. A., Gurvit, H. I., Ulutin, T., Dursun, E., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251329540 · Cited by 11
Self-citationInvolvement of IL-10R/STAT3 pathway in amyloid β clearance by microlgia in Alzheimer's disease
Liu, H., Zhou, Y., & Song, W. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108263 · Cited by 17
Wang, B., Liu, S., Hao, K.-M., Wang, Y., Li, Z., Lou, Y., Chang, Y., & Qi, W. (2024) · Experimental Brain Research · doi:10.1007/s00221-024-06858-z · Cited by 9
Zhang, H., Chi, M., Feng, S., Zhu, W., Wang, H., Zhou, W. P., Song, B., Wang, W., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1516975 · Cited by 8
Braden-Kuhle, P. N., Lacy, V. A., Brice, K. N., Bertrand, M. E., Uras, H. B., Shoffner, C., Fischer, B. E., Rana, A., Willis, J. L., Boehm, G. W., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251319467 · Cited by 8
“Given the reduced serum BDNF levels and increased pro-in fl ammatory cytokines in AD patients, 130,131 our results collectively suggest that the MD may prove protective against BDNF loss in an in fl ammatory state.”
Biomarkers of vascular cognitive impairment
Zimnitskaya, O. V., Mozheyko, E. Y., & Петрова, М. М. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2677 · Cited by 8
Akhgarjand, C., Mousavi, S. E., Kalantar, Z., Bagheri, A., Imani, H., Rezvani, H., Ghorbi, M. D., & Vahabi, Z. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.966933 · Cited by 9
“Although the main mechanism of memory decline is still uncertain, inflammatory states alongside homocysteine levels are presented as two possible pathological mechanisms (Bell et al., 1992; Rosenberg, 2001; Gezen-Ak et al., 2013; Ilkjaer et al., 2014).”
BackgroundGu, C., Gong, H., Zhang, Z., Yang, Z., & Ma, Y. (2016) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-016-0699-z · Cited by 8
Yagati, A. K., Park, J., Kim, J., Ju, H., Chang, K.-A., & Cho, S. (2016) · Japanese Journal of Applied Physics · doi:10.7567/jjap.55.06gn06 · Cited by 8
Zhou, W., Wang, Z., Tao, Y., Chen, C., Zhang, Q., Liu, Z., Li, L., Xia, P., & Ye, Z. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113320 · Cited by 7
He, J., Xie, P., An, X., Guo, D., Bi, B., Wu, G., Yu, W., Ren, Z., & Zuo, L. (2024) · Current Medical Science · doi:10.1007/s11596-024-2917-8 · Cited by 7
Khanthong, P., Sriyakul, K., Dechakhamphu, A., Krajarng, A., Kamalashiran, C., Jayathavaj, V., & Tungsukruthai, P. (2024) · European Journal of Physical and Rehabilitation Medicine · doi:10.23736/s1973-9087.24.08015-8 · Cited by 9
“37 When comparing the change in bdnf levels among four groups of participants with Mci (physical, mental, physical plus mental, and control), we found significantly different elevations only in the physical plus mental exercise and physical exercise groups.”
Backgroundde Aquino, A. M. I., Gomes, K. A. L., de Brito, L. L. M., de Lima, L. D., Gomes, E. R. D. M., & Andrade, S. M. (2024) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2023-0027 · Cited by 9
“This result is in line with that presented by Gezen-Ak et al. 29 , where serum TNF-α levels increased significantly only in the early-onset and late-onset AD groups, and, although these levels were higher in the MCI group than in the age-matched control group, they were not statistically significant.”
BackgroundResultInfluentialSokołowski, I., Kucharska-Lusina, A., Miller, E. D., Popławski, T., & Majsterek, I. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46100693 · Cited by 7
“The role of HSP90 in AD differs, with decreased levels in AD patients compared to controls [32].”
BackgroundZhang, J., Yue, D., & Zhang, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-87129-x · Cited by 6
Neuronal chloride transporters in neurodegenerative diseases
Yang, L., & Justice, N. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815318-5.00023-6 · Cited by 6
Increasing Effect of Citrus natsudaidai on Brain-Derived Neurotrophic Factor
Nakajima, K., Okubo, S., & Oiso, S. (2023) · Journal of Oleo Science · doi:10.5650/jos.ess22324 · Cited by 6
Testad, I., Kajander, M., Frøiland, C. T., Corbett, A., Gjestsen, M. T., & Anderson, J. G. (2019) · Research in Gerontological Nursing · doi:10.3928/19404921-20190813-02 · Cited by 6
Yasutaka, Y., Watanabe, T., Nakashima, A., Matsumoto, J., Futagami, K., Yamauchi, A., & Kataoka, Y. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.12.007 · Cited by 5
Mitroshina, Е. V., Krivonosov, M., Pakhomov, A. M., Yarullina, L. E., Gavrish, M. S., Mishchenko, T. A., Yarkov, R. S., & Vedunova, M. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512286 · Cited by 5
Yan, Y., Ma, M., Cai, W.-C., Huang, C., Lin, R., Chen, Y., & Li, H. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-02961-4 · Cited by 5
“, decreased Aβ-42 and increased phosphorylated tau) [37, 72, 73], identifying a means of modulating the levels of neuroprotective growth factors and pro-inflammatory cytokines would represent an important advance in AD treatment [74].”
BackgroundÇamoğlu, T., Yurttaş, Z., Kina, U. Y., Süt, P. A., Şahin, F., Dursun, E., & Gezen‐Ak, D. (2024) · ACS Omega · doi:10.1021/acsomega.3c10036 · Cited by 5
Self-citationAdvances in how the peripheral immune system interacts with the brain in health and disease
Ruiz-Rodríguez, V. M., Cuellar-Santoyo, A. O., & Estrada‐Sánchez, A. M. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.12.059 · Cited by 4
Jun, H., Lee, J., Park, B. O., Kim, R. W., Leem, J., & Kwon, K. (2025) · Journal of Functional Foods · doi:10.1016/j.jff.2025.106942 · Cited by 3
A Novel Bead-Based Immunoassay for the Measurement of Heat Shock Proteins 27 and 70
Njemini, R., Verhaeghen, K., Mets, T. F., Weets, I., & Bautmans, I. (2020) · Pathogens · doi:10.3390/pathogens9110863 · Cited by 3
Serum biomarkers in normal pressure hydrocephalus
Mehmedika-Suljić, E., Izetbegović, S., Serdarević, N., Rovčanin, B., Mahmutbegović, N., Mehičević, A., & Omerhodžić, I. (2023) · Medicinski Glasnik · doi:10.17392/1590-23 · Cited by 3
Upregulation Effect of Citrus Species on Brain-Derived Neurotrophic Factor
NAKAJIMA, K., Ahreum, H. A. N., KAYANO, A., & Oiso, S. (2024) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.70.61 · Cited by 3
Serum and Saliva Biomolecules in Periodontitis Patients with and without Alzheimer’s Disease
Öztürk, D., Midi, İ., Alaylıoğlu, M., Tuncer, E., Gezen‐Ak, D., Dursun, E., & Doğan, B. (2025) · Nigerian Journal of Clinical Practice · doi:10.4103/njcp.njcp_254_24 · Cited by 5
Self-citationPetersen, M. E., Gross, T. J., O’Bryant, S. E., & Mapstone, M. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818845-3.00018-9 · Cited by 2
Cullen, S. (2017) · Scholarship@Western (Western University) · Cited by 2
Blood brain-derived neurotrophic factor as a biomarker of Alzheimer's disease
Balietti, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815854-8.00018-5 · Cited by 2
The pathophysiological signaling and efficacy of medicinal herbal compounds in Alzheimer’s disease
Darabi, S., Ariaei, A., Gorgich, E. A. C., Rezaei, S., Behruzi, M., Abasian, Z., & Rustamzadeh, A. (2025) · Physiology and Pharmacology · doi:10.61186/phypha.29.1.3 · Cited by 1
Neuroinflammation in early and late onset Alzheimer´s disease: a multimodal analysis
Taipa, R. J. F. (2018) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 1
Plasticity in the sensorimotor system and innovative sensorimotor training in frailty
Beier, F. (2023) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00033327 · Cited by 1
Molecular Aspects of Concussion and Chronic Traumatic Encephalopathy
Farooqui, A. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813596-9.00008-0
Hu, Q. (2016) · TSpace (University of Toronto)
The Impact of Database Research on Industrial Products (Panel Summary).
Barbará, D., Blakeley, J. A., Fishman, D., Lomet, D., & Stonebraker, M. R. (1994)
Progress of Nanotechnology-Based Detection and Treatment of Alzheimer’s Disease Biomarkers
Singh, Y. R., Shukla, A., & Pattanayek, S. K. (2022) · Springer eBooks · doi:10.1007/978-981-16-3667-7_3 · Cited by 2
Alzheimer’s Disease: Link to Biomolecular Mechanisms and Clinical Pathologies
Gezen‐Ak, D., & Dursun, E. (2024) · doi:10.69860/nobel.9786053359166.4
Self-citationFábregas, C., Esteban-López, M., Fadó, R., Casals, N., Unzeta, M., Rodríguez-Álvarez, J., Miñano-Molina, A. J., & Solé, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.04.641410
“AD patients present diminished serum, plasma and cerebrospinal fluid BDNF concentrations compared to controls (Gezen-Ak et al., 2013).”
Alzheimer’s Disease: Link to Aging and Epigenetics
Zala, D. K., Banerjee, S., & Tiwari, A. K. (2025) · RNA technologies · doi:10.1007/978-3-031-91072-2_15 · Cited by 1
Molecular chaperone and chaperone-based therapeutic approaches for Alzheimer’s disease
Anand, T., & Kumar, A. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.11.006
Haidary, M., Ansari, M., Ansari, S., Rezayee, H., Hanifi, S., & Hossaini, D. (2025) · Alcoholism Treatment Quarterly · doi:10.1080/07347324.2025.2603655
“Notably, BDNF levels have been shown to increase post-alcohol withdrawal as part of a neuroadaptive response (Girard et al., 2020), while IL-10 reductions exacerbate neuroinflammation (Cui et al., 2024; Gezen-Ak et al., 2013).”
Mazo, C. (2024) · Deep Blue (University of Michigan) · doi:10.7302/23782
Yuanjiao, Y., Ma, M.-P., Cai, W.-C., Huang, C.-S., Lin, R., Chen, Y.-F., & Li, H. (2022) · Figshare · doi:10.6084/m9.figshare.19547229
Brosseron, F., Maaß, A., Kleineidam, L., Ravichandran, K. A., Kolbe, C.-C., Wolfsgruber, S., Santarelli, F., Häsler, L. M., McManus, R. M., Ising, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22602371
dos Santos, J. M. M., de Moura, A. B., Medeiros, E. B., Generoso, C. M., Tietbohl, L. T. W., Lídio, A. V., Steiner, B. T., Scussel, R., Dal‐Bó, A. G., Budni, J., et al. (2026) · Neuropeptides · doi:10.1016/j.npep.2026.102609
森, 友. (2021) · Institutional Repositories DataBase (IRDB)
Neurotrophins and Galectin-3: Hidden Keys in Neuroinflammation—A Narrative Review
Marković, B. S., Corovic, I. F., Mitrović, M. M., Jovicic, N. U., Selaković, D., Sreckovic, M. J., & Rosic, G. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093742
“…including patients with early-onset AD (EOAD), late-onset AD (LOAD), and mild cognitive impairment (MCI), serum BDNF levels were significantly reduced in both EOAD and LOAD patients compared with age-matched controls, while the pro-inflammatory cytokine TNF-α was significantly elevated [142].”
Vélez, F. G. S., Cedeno-Bruzual, M., Gutiérrez, M. Z., Pena, D. M., Ballard, C., Kong, J. S., Pinaffi‐Langley, A. C. D. C., Owens, C. D., TucsekCardon, Z., Szarvas, Z., et al. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1778992 · Cited by 1
“…and altered expression of neurotrophic factors (NTFs) such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor, and ciliary neurotrophic factor have been observed in dierent brain regions (Gezen-Ak et al., 2013; Lee et al., 2009).”
The Power of Stem Cells and Neurotrophic Factors in the Quest for Alzheimer’s Disease Therapies
Costa, I., Barbosa, D. J., & Silva, R. V. D. S. (2026) · Springer handbooks · doi:10.1007/978-3-032-01636-2_24
Rezayee, H., Haidary, M., Hossaini, D., Akbari, E., Nazari, M. L., Ilbeigi, D., & Saadat, M. (2026) · Alcoholism Treatment Quarterly · doi:10.1080/07347324.2026.2716244
“Notably, BDNF expression has been reported to increase following ethanol withdrawal as part of a compensatory neuroadaptive response (Girard et al., 2020), while decreased IL-10 levels are associated with enhanced neuroinflammatory signaling (Cui et al., 2024; Gezen-Ak et al., 2013).”
Shanehbandpour-Tabari, F., Golchoobian, R., & Pourabdolhossein, F. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179245
Qiao, Q., Katsumata, Y., Lai, H.-Y., Lin, K. Z., Claas, S. A., Gabitto, M. I., Morganti, J. M., Nelson, P. T., Mukherjee, S., & Fardo, D. W. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71810
Tang, H., Fachim, H., Harte, M., & Reynolds, G. P. (2026) · Journal of Neural Transmission · doi:10.1007/s00702-026-03280-3
“…identified a marked reduction in BDNF protein (Hock et al. 2000) and mRNA expression (Holsinger et al. 2000) in the brains and peripheral blood (Gezen-Ak et al. 2013) of individuals with AD, in which the reported reduction correlates with cognitive decline and the neuronal loss characteristic…”
Metadata
- Authors
- Gezen-Ak, D., Dursun, E., Hanağası, H., Bilgiç, B., Lohman, E., Araz, Ö. S., Atasoy, İ. L., Alaylıoğlu, M., Önal, B., Gürvit, H., & Yılmazer, S.
- Affiliations
- Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
- Istanbul University-Cerrahpaşa (TR)
- Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
- Istanbul University (TR)
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2013-08-20
- Volume
- 37
- Issue
- 1
- Pages
- 185-195
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1612435886
- Cited by
- 188
- References
- 22
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 13 · 2023: 14 · 2022: 12 · 2021: 13 · 2020: 22 · 2019: 16 · 2018: 20 · 2017: 13 · 2016: 18 · 2015: 14 · 2014: 10
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, mild cognitive impairment
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Enzyme-Linked Immunosorbent Assay, Humans, Middle Aged, Regression Analysis, Tumor Necrosis Factor-alpha, Turkey, Cohort Studies, Biomarkers, Case-Control Studies, Interleukin-10, Complement Factor H, Age of Onset, HSP90 Heat-Shock Proteins, Brain-Derived Neurotrophic Factor, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.